Metformin treatment decreased HER2/IGF-1R activity (while HER2 expression remains unaffected) specifically in the trastuzumab-resistant forms of the HER2-overexpressing (BT474 and SKBR3) breast cancer cells. The gene discussed is ERBB2; the disease is breast cancer.